# OnCo record isotypes-and-fc-silencing (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/isotypes-and-fc-silencing/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "isotypes-and-fc-silencing" ;
  schema:name "Antibody isotypes and Fc silencing"@en ;
  schema:alternateName "antibody isotype"@en, "isotype"@en, "IgG subclass"@en, "Fc silencing"@en, "class switching"@en ;
  schema:description "An antibody's class and the design of its stem change how it connects to immune cells and complement. Switching off one connection does not switch off all of them, and does not make the finished drug harmless."@en ;
  schema:url <https://onco.cc/terms/isotypes-and-fc-silencing/> ;
  schema:dateModified "2026-11-09"^^xsd:date ;
  schema:citation <https://doi.org/10.3389/fimmu.2014.00520>, <https://doi.org/10.1074/jbc.M116.767749>, <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s194lbl.pdf>, <https://doi.org/10.1126/science.1118948>, <https://openstax.org/books/microbiology/pages/18-4-b-lymphocytes-and-humoral-immunity> ;
  onco:tag "education-immunology-2026-11" ;
  onco:related <https://onco.cc/terms/fc-effector/>, <https://onco.cc/terms/antibody/>, <https://onco.cc/terms/adcc-adcp-cdc/>, <https://onco.cc/terms/half-life/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/antibody-structure/> ;
  onco:targets <https://onco.cc/targets/fcgr3a/>, <https://onco.cc/targets/fcgr2a/>, <https://onco.cc/targets/fcgr2b/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/fc-effector/>, <https://onco.cc/terms/antibody/>, <https://onco.cc/terms/half-life/>, <https://onco.cc/terms/antibody-structure/>, <https://onco.cc/terms/adcc-adcp-cdc/> .
